FREEHOLD, N.J., Feb. 04, 2020 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, announced today that its President and Chief Executive Officer, David Jin, M.D., Ph.D., will co-chair a session, entitled “Cellular Therapy in the Asia Pacific Region,” at the Transplantation & Cellular Therapy (TCT) Meetings in Orlando, Florida. TCT Meetings are the combined annual meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR).
The session, “Cellular Therapy in the Asia Pacific Region,” will provide a venue to review and examine the current status and future trends in cellular therapy (particularly immune effector cell therapy, such as CAR-T), within Asia and the Pacific Rim region.  Invited speakers and panelists will present topics about their expertise and experience on clinical protocols, outcome analysis, regulatory affairs, standardization, and accreditation related to cellular therapy during this session.“We are honored to lead this session and panel discussion at the industry renowned TCT Meetings, comprising the leading experts in a rapidly evolving cellular therapy ecosystem in the Asia Pacific region. We look forward to leveraging our respective experience and capabilities in cell-based technologies and therapeutics. We will contribute our scientific, regulatory, clinical and commercial expertise to help empower high impact, transformative cell-based technologies and their clinical applications,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare.About Avalon GloboCare Corp.Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth, development, as well as competitiveness in healthcare and CellTech industry markets.  Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of in vitro diagnostics (”liquid biopsy”), immune effector cell therapy (including CAR-T/CAR-NK), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.Forward-Looking StatementsCertain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
[email protected]Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
[email protected]
Bay Street News